Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents

Journal of Medical Economics

Volumn 16, Issue 8, 2013, Pages 1071-1081

  Byfield, Stacey Dacosta ^a   Yu, Elaine ^b   Morlock, Robert ^b   Evans, Dana ^b   Teitelbaum, April ^a  

^a OPTUM   (United States)

^b GENENTECH INC   (United States)

Author keywords

Algorithm; Bevacizumab; Cetuximab; Healthcare costs; Metastatic colorectal cancer; Second line treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADULT; ALGORITHM; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84880548865     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.813513     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28
3. Howlader N, Noone AM, Krapcho M, et al.; SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). 2011. http://seer.cancer.gov/csr/1975- 2009-pops09/results-merged/sect-06-colon-rectum.pdf. Accessed March 6, 2013
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83
5. Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830. doi: 10.1155/2012/406830. Epub 2012 May 17
6. Genentech Inc. Avastin-(bevacizumab). Prescribing information. 2013. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf. Accessed March 6, 2013
7. Bristol-Myers Squibb. Erbitux-(cetuximab) prescribing information. 2012. http://packageinserts.bms.com/pi/pi-erbitux.pdf. Accessed March 6, 2013
8. Amgen I. Vectibix-(panitumumab) presribing information. 2013. http://pi.amgen.com/united-states/vectibix/vectibix-pi.pdf. Accessed March 6, 2013
9. Bayer HealthCare Pharmaceuticals IncBayer HealthCare Pharmaceuticals I. Stivarga (regorafenib). Prescribing information. 2013. http://labeling. bayerhealthcare.com/html/products/pi/Stivarga-PI.pdf. Accessed March 6, 2013
10. Regeneron Pharmaceuticals I. Zaltrap-(ziv-aflibercept). Prescribing information. 2012. http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf. Accessed March 6, 2013
11. Liang SY, Phillips KA, Wang G, et al. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 2011;49:e1-8
12. Lund JL, Sturmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care 2013;51:e27-34
13. Yang H, Yu AP, Wu EQ, et al. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ 2011;14:542-52
14. Hess GP, Wang PF, Quach D, et al. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6:301-7
15. US Department of Health and Human Services. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. http://www.cms.gov/Regulations-and-Guidance/HIPAA-Administrative-Simpl ification/HIPAAGenInfo/TheHIPAALawandRelated-Information.html. Accessed March 6, 2013
16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
17. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidlines in oncology. Colon cancer. Version 3 2013. http://www.nccn.org/ professionals/physician-gls/pdf/colon.pdf. Accessed March 6, 2013
18. US Department of Labor BoLS. Consumer Price Index. Chained Consumer Price Index. 2010. http://data.bls.gov/cgi-bin/surveymost?su. Accessed March 6, 2013
19. Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. Am J Manag Care 2011; 17(Suppl 5):SP20-5
20. Zafar SY, Marcello JE, Wheeler JL, et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009;5:228-33
21. Ferro SA, Myer BS, Wolff DA, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care 2008; 14:717-25